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Background: The purpose was to determine whether a brachytherapy boost improves outcomes in patients with
advanced nasopharyngeal carcinoma treated with standard chemo-radiotherapy.
Methods: Patients with nasopharyngeal carcinoma WHO grades I-III and TNM stages III or non-metastatic stage IV
were eligible for this phase III study. Patients were randomized to either arm (A) induction chemotherapy, followed
by external beam radiotherapy (EBRT) with concomitant cisplatin (n = 139) or arm (B), the same schedule plus a
brachytherapy boost to the nasopharynx (n = 135). The EBRT doses given were 70 Gy to the primary tumour and
positive lymph nodes and 46 Gy to the negative neck. The additional brachytherapy boost in arm (B) was given by
either low dose-rate (LDR – 11 Gy) or high dose-rate (HDR – 3 fractions of 3.0 Gy) brachytherapy. The primary endpoint
was 3-year overall survival (OS) and secondary endpoints were: local control, regional control, distant metastasis and grade
3–4 adverse events.
Results: 274 patients were randomized between September 2004 and December 2008. The two arms were comparable
with regard to age, gender, stage and grade. 273 patients completed treatment. Median follow-up was 29 months
(0.2-67 months). The effect of treatment arm, country, age, gender, WHO pathology, stage (T3-4, N2-3 versus other) and
chemotherapy on overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS) was studied.
Stage significantly affected OS (p = 0.024) and DFS (p = 0.018) while age significantly affected OS (p = 0.014). None of the
other factors studied were significant. The 3-year LRFS was 60.5% and 54.4% in arms A and B respectively (p = 0.647). The
3-year regional control rate in the neck was 59.7% and 54.3% respectively (p = 0.7). Distant metastasis developed in 59.7%
of patients in arm A and 55.4% in arm B (p = 0.377). Patients with T1/T2 N + had a 3 year LRFS of 51.8% in Arm A (62
patients) versus 57.9% in Arm B (67 patients) (p = 0.343). The grade 3–4 toxicity rate was 21.6% (30/139) and 24.4%
(33/135) respectively (p = 0.687).
Conclusions: The addition of a brachytherapy boost to external beam radiotherapy and chemotherapy did not
improve outcome in loco-regionally advanced nasopharyngeal carcinoma.
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Nasopharyngeal carcinoma (NPC) is among the cancers
which are common and potentially curable with radio-
therapy in Asia and North Africa. However, patients
treated with radiotherapy alone have a cumulative inci-
dence of persistent local disease of up to 13% and a 10-
year actuarial local failure-free survival of 61% [1]. Thus,
local recurrences represent a significant component of
radiation failures. In addition to local symptoms related
to local recurrence, lack of local control is an independ-
ent prognostic factor for the development of distant me-
tastases. Local control may be related to the total dose
of radiation given through external beam radiotherapy
(EBRT) alone or combined with brachytherapy. Previous
studies report an acceptable incidence of side effects
with cumulative doses of up to 81 Gy to the nasophar-
ynx proper [2-4]. Neoadjuvant chemotherapy was found
to improve outcomes in randomized studies. Al-Sarraf
et al. [5] reported a significant improvement in 3-year
survival (78% vs. 47%) as well as reduction in local and
distant failure rates in the arm that received concomitant
cisplatin and adjuvant chemotherapy.
The present study was designed to determine the po-
tential clinical benefit of radiotherapy dose escalation
using brachytherapy, in addition to the standard external
beam radiation and chemotherapy commonly used in
the treatment of nasopharyngeal carcinoma, in patients
with locally- or loco-regionally advanced disease.
The present study was a multicentre, international clin-
ical trial coordinated by the International Atomic Energy
Agency (IAEA), with data management and statistics con-
ducted at the National Cancer Institute of Cairo, Egypt and
patient accrual and treatment implemented in radiotherapy
centres in Egypt, Algeria, Morocco, Pakistan and Thailand.
Patients and methods
The protocol was approved by the Institutional Review
Board of the participating hospitals and all patients pro-
vided informed consent before trial entry. Adult patients
with histopathologically proven nasopharyngeal carcin-
oma (WHO type I-III) and T3-T4 N0-3 or T1-T2, N2,
N3 disease, according to the TNM classification of the
Union for International Cancer Control (UICC), 5th edi-
tion, were eligible for inclusion in the study. Patients
had to be over 15 years of age and have an Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus of 0–2 to be eligible. Laboratory tests had to be
within normal range and patients with inadequate haem-
atological, renal or hepatic function were excluded (i.e.:
Hgb <10 g/dl, WBC < 4000, absolute neutrophil count
(ANC) <1500, platelets < 100,000, serum bilirubin >1.5 mg/
dl, serum creatinine >1.5 mg/dl). Patients were ineligible
for trial participation if they were pregnant or lactating, if
they had metastatic (M1) disease, if they were previouslytreated for their cancer, or had a simultaneous or prior ma-
lignancy with the exception of non-melanoma skin cancers
or carcinoma in-situ of the cervix.
Work-up of study patients included the following labora-
tory tests: complete blood count (CBC), liver function tests
and renal function tests (BUN, serum creatinine/creatinine
clearance). Imaging included chest x-ray, head and neck
CT-scan and abdominal ultrasound. Cardiac function was
evaluated by ECG and left ventricular ejection fraction.
Bone scan/skeletal survey and serum alkaline phosphatase
were used to assess for bone metastases. Bone scan was
mandatory in case of bone symptoms or elevated serum al-
kaline phosphatase. Pre-treatment oral/dental consultation
was required for all patients.
The standard arm included neoadjuvant chemotherapy
and concurrent chemo-radiation therapy, consisting of
EBRT alone. Treatment in the study arm consisted of a
similar regimen of neoadjuvant chemotherapy, concurrent
chemo-radiation therapy with EBRT plus the addition of a
brachytherapy boost.
Neoadjuvant chemotherapy consisted of cisplatin:
100 mg/m2 and doxorubicin 50 mg/m2 or Epirubicin
75 mg/m2, with hydration, diuretics and antiemetic drugs.
Neoadjuvant chemotherapy was given every 3 weeks for
2 cycles. The first course of neoadjuvant chemotherapy was
given on day 1 and the second course on day 22. Each
course was postponed for 1 week if the CBC was not ac-
ceptable for treatment (WBC < 3000; ANC< 1500; Platelet
< 80 000). Chemotherapy was discontinued if there was no
improvement in CBC, if intercurrent disease occurred, if
creatinine was >1.5 times the normal level or if the patient
refused further chemotherapy. Chemotherapy was also
discontinued if the patient developed cardiac symptoms
and/or ECG and echocardiography were to be done to
monitor cardiac function.
Neoadjuvant chemotherapy was followed by EBRT
starting between day 43 to day 50 and concurrent weekly
cisplatin 30 mg/m2 /week throughout the radiotherapy
course (7 weeks). Radiation therapy was scheduled to
start within 6 hours of the cisplatin infusion. Subsequent
to the completion of the external beam radiation, only
patients randomized to the experimental arm received a
brachytherapy boost. Per protocol, brachytherapy was to
be given within 1 week of the completion of EBRT.
Concomitant chemotherapy could be stopped for the
same reasons as neoadjuvant chemotherapy. Radiation
therapy could be delayed for up to one week if grade
3–4 hematologic toxicities were seen.
Megavoltage machines were used (Co-60 or 4–6 MV
linear accelerators) with mask immobilization in an ex-
tended neck position. The treatment fields, shielding
blocks and entrance point of each field were marked
on the mask. Nodal masses in the neck were marked
with metallic wire. Simulator films were taken. The total
Figure 1 The Rotterdam nasopharyngeal applicator for
brachytherapy.
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tion) given over 7 weeks.
The initial treatment volume included the primary
tumour and its extensions, posterior and upper deep
cervical lymph nodes which were treated through two
parallel opposed lateral fields. Setting the field junction
over enlarged lymph nodes was avoided when possible.
The clinical target volume included the nasopharynx,
the skull base, the sphenoidal and posterior ethmoid si-
nuses, the floor of the middle cranial fossa, the posterior
half of the nasal cavity and orbit, the lateral pharyngeal
walls and the parapharyngeal space, inferior extension to
the oropharynx, posterior cervical, deep cervical and
supraclavicular lymph nodes. The lower border of the
lateral fields was placed high in the neck to avoid the
unnecessary inclusion of the larynx. The optic chiasm,
brainstem, anterior half of the orbit and a portion of the
oral mucosa were shielded if there was no tumour
extension. Patients with anterior nasal extension were
treated with an additional anterior photon field. Mid and
low cervical nodes were treated through a direct anterior
field. If there were very large cervical lymph nodes; two
large lateral opposed fields extending from skull base to
the clavicles were used to avoid placing a field junction
over the area of lymph node disease whenever possible.
Reassessment of the lymph node size was carried out at
20–40 Gy. The treatment fields were then modified into
two parallel opposed lateral fields to the upper head and
neck and a direct anterior lower neck field as long as the
lymph node size reduction was sufficient to avoid field
junction over the lymph nodes. For the initial fields, the
dose to the primary tumour was 40 Gy/20 fractions/
4 weeks (2 Gy /fraction). Regional neck lymph nodes re-
ceived doses based on lymph node stage: N0 dose was
46 Gy at 3 cm depth, with an off cord field modification
after 40 Gy to allow for an electron field over the poster-
ior neck to deliver 6 Gy /2-3 fractions /2-3 days. For the
boost portion of the treatment with EBRT, the primary
tumour site and extensions was treated with two lateral
opposed reduced fields. The whole lower neck was
treated through a large direct anterior field with shield-
ing of the spinal cord. The posterior spinal lymph nodes
were treated with electron beam (> 9 MeV). Optic chi-
asm, optic nerves and cervical spinal cord limits of not
more than 45 Gy were allowed. The doses delivered
through the boost field were as follows: primary tumour:
30 Gy/15 fractions/3 weeks; regional lymph nodes: N1-3:
30 Gy. Therefore, the final total dose to the primary
tumour and clinically involved lymph nodes was 70 Gy
and 46 Gy to the clinically negative neck.
The silicone Rotterdam Nasopharynx Applicator [6]
(Figure 1) was used to deliver brachytherapy in the
experimental study arm. Investigators were specifically
trained in the use, insertion, imaging and dosimetry ofthe Rotterdam applicator which was used in all cases
since this applicator allows for either low-dose-rate
(LDR) or high-dose-rate (HDR) brachytherapy.
The applicator was introduced transorally under top-
ical anaesthesia, and fixed in position in the nasal cavity
and nasopharynx. Then, standard afterloading catheters
were inserted into the applicator’s silicone tubes. In case
of LDR, two Ir-192 wires with an average activity of
50–60 mCi/cm, were inserted into both afterloading
catheters. For HDR, the afterloading catheters were con-
nected to a remote-controlled afterloader (Ir-192 microSe-
lectron HDR). The applicator remained in place for the
duration of the treatment for both LDR- and HDR endo-
cavitary irradiation. In case of LDR, the active source
was tailored to the nasopharynx proper that is to the
distance between the ‘Node of Rouviere’ (at the level
of the C-I vertebral body), [6] (Figure 2) and the pter-
ygoid plates. The Ir-192 source was removed after a
dose of 11 Gy was delivered to the nasopharynx “tumour
tissue” (TT) point. For HDR, a boost dose of 9.0 Gy
in 3 fractions of 3.0 Gy each was delivered with a
minimum interval of 6 hours between fractions. The
dose was prescribed to the “tumour tissue” (TT) points
‘Node of Rouviere (R)’ and/or ‘Nasopharynx (Na)’. The
dose distribution for LDR and HDR was computed in
the ‘Tumour Tissue (TT)’ points ‘Na’ and ‘R’, as well
as in the critical normal tissue (NT) points represent-
ing the soft palate, base of skull, pituitary gland, optic
chiasm, and retina. Other optional points representing
normal tissue were the temporal lobes, and inner ear.
These dosimetry points have been previously described by
Levendag et al. [6].
In the study arm, both low dose-rate (LDR) and high
dose-rate (HDR) brachytherapy were allowed for the
Figure 2 Dosimetry points for the Rotterdam nasopharyngeal applicator in the lateral view: 1 Node of Rouvière point, 2 Spinal cord point,
3 Pituitary gland, 4 Optic chiasm, 5 Retina, 6 Soft palate, 7 Base of skull, 8 Nasopharynx, 9 Temporal lobe, 10 Inner ear, 11 Pterygoid plates.
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were: for LDR: 11 Gy to the “nasopharyngeal tumour tis-
sue point” and for HDR: 3 fractions of 3.0 Gy each (total:
9.0 Gy) to the same point, with a minimum interval of
6 hours between fractions. RTOG (Radiation Therapy
Oncology Group) acute radiation morbidity scoring cri-
teria and RTOG/EORTC (European Organization for
the Research on the Treatment of Cancer) late radiation
morbidity scoring criteria were used to assess toxicity.
Statistics
Stratification according to treating centre and stage
(T4N3 vs. others) was done. The primary endpoint was
overall survival at 3 years. It was hypothesized that the
survival rate would be 65% (or greater) in the experi-
mental arm versus 50% in the control arm. Secondary
endpoints included: response rate at 40 Gy, local control
rate (local relapse-free survival), rate of distant metasta-
ses (distant metastases free survival) and toxicity rate.
Response rate at 40 Gy was not evaluated in the final
analysis due to insufficient data. Patients were random-
ized to two arms, a standard/control and a study arm.
A sample size calculation was done to determine the
number of patients needed in each arm to allow a com-
parison of 50% survival rate with the control treatment,
to the study arm with an hypothesized survival rate
of 65%, for a test of significance level of 0.05 and 80%
power. Interim analyses were planned to allow early
termination of the study if the number of treatment-
related deaths in the experimental arm exceeded 4 or ifthe absolute difference in survival between the two arms
exceeded 20%.
Results
Between September 2004 and December 2008 a total of
274 eligible patients were centrally randomized to either
the standard arm (arm A) which consisted of 2 courses
of induction chemotherapy, followed by external beam
radiotherapy with concomitant cisplatin (n = 139) or the
study arm (arm B) which consisted of the same schedule
plus an additional brachytherapy boost to the nasophar-
ynx using the Rotterdam applicator (n = 135). One pa-
tient who was initially randomized to the study arm was
immediately lost to follow up and had no outcome data;
therefore, was not included in the analyses. The distribu-
tion of stage, gender and histological grades were statis-
tically comparable in both treatment arms (Table 1).
However, patients in the study arm were younger by ap-
proximately 3.5 years (p = 0.044). The median follow-up
was 29 months (2–67 months) and 9% patients were lost
to follow-up. The patients received treatment as follows:
Two hundred and seventy-five patients were found
eligible and randomized. Age, gender and the distribution
of stages and histological grades were statistically compar-
able in both treatment arms. 94% of patients completed the
treatment as planned. The median follow-up was 29 months
(2–67 months) and 9% patients were lost to follow-up.
External beam radiation: 257 patients received 70 Gy
in 35 2.0 Gy fractions with EBRT. Seven patients had
missing dose information. An additional eight patients
Table 1 Patients’ demographics in the two study arms
Standard Brachytherapy
n = 139 n = 135
Measurement n (%) n (%) P-value**
Age (years)* 43.5 ± 13.6 40.0 ± 14.8 0.044
Gender Male 104 (74.8) 94 (69.6)
Female 35 (25.2) 41 (30.4) 0.337
WHO histology 1-2 29 (20.9) 37 (27.4)
3 110 (79.1) 98 (72.6) 0.205
Stage T3-4&N2-3 34 (24.5) 36 (26.7)
Others 105 (75.5) 99 (73.3) 0.676
Neoadjuvant chemo Yes 120 (86.3) 119 (88.1)
No 19 (13.7) 16 (11.9) 0.652
*Value is mean ± standard deviation. **P-values ≤ 0.05 are considered significant.
P-values ≤ 0.05 are considered significant.
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patient), 30 Gy (1 patient), 40 Gy (4 patients), 56 Gy (1
patient), 57 Gy (1 patient). Also, there was one add-
itional patient who refused external beam radiation in
the standard arm. Thus, of 273 patients 272 had external
beam radiation therapy, 94% of them to the prescribed
protocol dose.
Out of the 135 patients who were randomized to the
experimental arm, one hundred and seven patients did
receive the brachytherapy treatment (80%), twenty five
patients did not, and data was missing on two patients.
Patients had the brachytherapy procedure done a median
of 10 days after the external beam radiation ended (range
0–52 days). Of the remaining patients who received brachy-
therapy implants, 30 (22%) had the procedure within a
week of completing the EBRT. Brachytherapy implants
were done at 2, 4 and 6 weeks or over 6 weeks in the
remaining 39, 22, 10 and 3 patients, respectively.
One hundred and forty nine patients received 70 Gy
in 35 fractions. One hundred and eight patients received
doses somewhat higher than 70 Gy (79 Gy and 81 Gy in
61 and 47 patients respectively). The cumulative (com-
bined external beam and brachytherapy) radiation doses in
the remaining patients were as follows: 10 Gy (1 patient),
30 Gy (1 patient), 40 Gy (2 patients), 51 Gy (2 patients),
56 Gy (1 patient), 57 Gy (1 patient). One patient random-
ized to the standard arm, subsequently refused treatment.
Cisplatin concomitant chemotherapy was used in all
patients, with the exception of 3 patients who received
no concomitant chemotherapy, two in the standard arm
and one in the study arm.
Information about the number of cycles was available
in most patients. Twenty three of 139 patients (17%) in
the standard arm did not receive neoadjuvant chemo-
therapy. In the brachytherapy arm, 16 of the 135 patients
(12%) did not receive neoadjuvant chemotherapy. In thestandard arm, the number of chemotherapy cycles given
was 2 cycles in 111 patients (23 received cisplatin/5FU;
88 received cisplatin/doxorubicin) and 1 cycle in two
patients (one of each chemotherapy regimen). In the
brachytherapy arm, the number of chemotherapy cycles
given was 2 cycles in 115 patients (85 received cisplatin/
doxorubicin and 30 received cisplatin/5FU).
Although not part of the initial study endpoints, a
comparative analysis between induction chemotherapy
with cisplatin/doxorubicin (n = 155, 57%) and patients
who received cisplatin/5FU (n = 118, 43%) showed a
3-year DFS rate of 62.3% for the former and 53.9% for the
latter (p = 0.001) indicating that induction treatment
with cisplatin/5FU was inferior. A multivariate analysis of
prognostic factors showed that only TNM stage and
chemotherapy with cisplatin/5FU (118 patients −43%-
treated in Algeria) were adverse prognostic factors for
survival in this series.
One hundred and fifty-five patients were to receive
cisplatin/doxorubicin, while 118 patients at one specific
centre received cisplatin/5FU (Table 2). When patients
receiving cisplatin/5FU are compared to patients who
received cisplatin/doxorubicin, no significant difference
was seen in age (p = 0.739), gender (p = 0.109), WHO
histology (p = 0.174), but there was a significant differ-
ence observed in stage (p = 0.034).
Results by study arm
Overall survival, local relapse free and disease free sur-
vival were not significantly different between treatment
arms (Figures 3 and 4). The 3-year overall survival rate
was 62.9% and 63.3% (p = 0.742) (Figure 3) for standard
and study arms, respectively; while the 3-year disease-
free survival was 59.8% and 52.6% (p = 0.496) (Table 3).
The 3-year local recurrence free survival rate was
60.5% and 54.4% (p = 0.647) (Figure 4) for the standard
Standard 139 93 67 41 12 1 0
Brachytherapy134 100 66 40 14 2 0
Figure 4 Local recurrence free survival by randomization
group. No statistically significant difference.
Table 2 Patient characteristics in the two groups that
received different neoadjuvant chemotherapy with
Cisplatin and Doxorubicin and patients from Algeria who
received Cisplatin and 5 FU
Algeria Other countries
n = 119 n = 155
Measurement n (%) n (%) P-value
Age (years)* 42.8 ± 13.3 41.0 ± 15.0 0.303
Gender Male 82 (68.9) 116 (74.8)
Female 37 (31.1) 39 (25.2) 0.277
WHO histology 1-2 24 (20.2) 42 (27.1)
3 95 (79.8) 113 (72.9) 0.184
Stage T3-4&N2-3 27 (22.7) 43 (27.7)
Others 92 (77.3) 112 (72.3) 0.342
*Value is mean ± standard deriation.
P-values ≤ 0.05 are considered significant.
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not significantly different between treatment arms, even
when stratified by different T and N stage combinations
(e.g.: T1-T2 N + versus others) (Table 4). Fifty one per-
cent of patients developed distant metastasis in arm A
and 46% in arm B (p = 0.377). Distant metastasis-free
survival (DMFS) was not significantly different by treat-
ment arm (p = 0.43).
Regional relapse free survival (RRFS) was not significantly
different by treatment arm (p = 0.70). The only factors
affecting regional relapse free survival were age <40 years
versus > 40 years (66.9% 50.6%; p = 0.047) and ad-
vanced stage T3-4, N2-3 vs. others (45.4% vs. 60.2%;
p = 0.023).
Analysis by actual treatment received (i.e. EBRT alone
versus EBRT and brachytherapy), rather than intention-
to-treat, also showed that brachytherapy did not signifi-
cantly affect local control (p = 0.906) or overall survival
(p = 0.819).Standard 139 108 80 50 22 2 0
Brachytherapy134 114 83 51 20 4 0
Figure 3 Overall survival by randomization arm. The difference
is not statistically significant (p = 0.742).Significant variables by Log rank test were entered into
a Cox Proportional Hazards model to study the inde-
pendent effect of the prognostic factors on all survival
estimates. Significant variables were stage (T3 or T4 and
N2 or N3 versus other stages) as well as age (<40 yrs vs
≥40 yrs). Although the treatment arms used were not a
significant factor, they were also entered into the Cox
model. Stage and age were still the only significant fac-
tors found after performing multivariate analyses. The
odds of death among patients with stage T3 or T4 and
N2 or N3 was 1.77 higher than the other stages, with a
(95% CI: 1.14-2.74) while the odds of death was 1.81
(95% CI: 1.17-2.80) higher among old age groups com-
pared to the younger age group.
Grade 3–4 toxicity rate was not significantly different
between study arms (Table 5).
Discussion
Rationale of using brachytherapy in the advanced-disease
setting
Modern radiotherapy techniques such as 3D conformal
radiotherapy, IMRT and stereotactic radiotherapy are the
mainstay of treatment of nasopharyngeal carcinoma with
very encouraging outcomes [7-11]. In low- and lower-
middle income countries however, many radiotherapy
centres still rely on a 2D technique to treat the numer-
ous patients referred to them. Until these centres adopt
3D-CRT as a standard, they will need to optimize the re-
sources available.
Several retrospective analyses have addressed the role
of a brachytherapy boost in nasopharyngeal carcinoma
[12-18]. These studies have looked at brachytherapy as a
technique to escalate the dose to the primary tumour
and extensions without incurring in unacceptable tox-
icity to surrounding sensitive organs. To our knowledge,
this is the first prospective randomized study of dose
Table 3 Patient’s characteristics and outcomes: overall survival, disease-free survival and local-recurrence free survival
Measurement Number of patients 3-year overall
survival (%)
P value* 3-year disease free
survival (%)
P value* 3-year local relapse
free survival (%)
P-value*
Treatment Standard 139 62.9 0.742 59.8 0.496 60.5 0.647
Brachytherapy 134 63.3 52.6 54.4
Country A 118 59.8 0.222 49.9 0.124 51.7 0.283
B 29 45.2 37.2 40.9
C 76 71.3 67.1 67.1
D 25 70.1 60.0 60.0
E 25 68.8 68.7 68.7
Age (years) <40 yrs 105 71.5 0.014 64.4 0.125 66.8 0.058
≥40 yrs 168 57.6 50.6 51.1
Sex Male 197 63.3 0.540 56.2 0.442 57.6 0.394
Female 76 61.5 55.8 56.6
WHO pathology 1-2 65 61.4 0.949 53.9 0.461 54.8 0.438
3 208 63.6 56.7 58.0
Stage T3-4 & N2-3 70 50.6 0.024 45.3 0.018 46.2 0.016
Others 203 66.5 59.3 60.6
Chemotherapy No 35 75.2 0.159 65.4 0.136 65.4 0.184
Yes 238 60.4 54.7 56.2
T Stage T1&T2 140 59.0 0.372
T3&T4 133 55.3
T Stage & N T1/T2N+ 129 54.9 0.683
Others 144 59.8
*P-value ≤ 0.05 is considered significant. WHO =World Health Organization. N = Lymph node status.
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Table 4 Three-year survival by treatment arm stratified
by T1-T2 N + stage
T – N stage Measurement Number of
cases
3 years
survival (%)
P-value*
T1&T2N+ Standard 62 51.8
Brachytherapy 67 57.9 0.343
Others Standard 77 67.9
Brachytherapy 67 50.0 0.106
T1&T2 Standard 70 58.2
Brachytherapy 70 60.1 0.641
T3&T4 Standard 69 63.2
Brachytherapy 64 46.3 0.205
*P-value ≤ 0.05 is considered significant.
T1&2; N1 203 170 130 87 38 6 0
T3&4; N2&3 70 52 33 14 5 --- ---
Figure 5 Overall survival by stage. TNM stage had a significant
impact on overall survival which was favourable for patients with
early disease (p = 0.024).
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beam radiation therapy in patients with advanced local
or loco-regional disease.
Patients with advanced loco-regional disease were spe-
cifically targeted for this study for two reasons: (1) they
represent the majority of patients with NPC seen in low-
middle income countries where the disease is common,
and (2) the brachytherapy boost was applied following
full high-dose external beam radiotherapy with neoadju-
vant as well as concomitant chemotherapy. Therefore,
the intention was to treat the residual disease after the
first phase of intensive treatment.
Of the published retrospective studies, some are lim-
ited by small patient numbers and differing stages and
pathology. In spite of these study limitations, several
authors have reported improvement in outcomes with
dose-escalation using brachytherapy in conjunction to
the standard external beam radiation. In 1980, Chang
et al. [19] was the first to report an improvement in sur-
vival with the addition of intracavitary radium brachy-
therapy to Cobalt-60 teletherapy (68.6% vs. 40.4%, p <
0.01). Furthermore, in a retrospective review of 509 pa-
tients, Teo et al. [16] reported an increase in local con-
trol when additional HDR brachytherapy was used after
external beam radiation therapy. This benefit of brachy-
therapy was not consistently reported, however. A recent
series from Haceteppe University [17] did not show anyTable 5 Late treatment toxicities
Arm 1 (No BT) Arm 2 (BT) P-value
GI-II GIII-IV GI-II GIII-IV
Skin 137 2 130 5 0.277
Subcutaneous tissue 136 3 132 3 1.000
Mucous membranes 138 1 131 4 0.209
Salivary glands 131 8 126 9 0.806
Brain 138 1 135 0 1.000
Trismus 124 15 123 12 0.687improvement in local control in patients treated with
additional brachytherapy implant after external beam ra-
diation as compared to external beam radiation alone
(86% vs. 94%; p = 0.23). One explanation may be that the
patients in the EBRT alone arm were significantly youn-
ger and more likely to receive chemotherapy which may
have favourably affected their outcomes. Furthermore,
patients received brachytherapy 4–6 weeks after EBRT
which may have influenced the results due to a protracted
overall treatment time. On the other hand, the longer inter-
val may also allow time for a decrease in tumour size, thus
enhancing the brachytherapy dosimetry. The results of the
latter study concurred with the findings from the present
study where no differences in outcome were seen when an
additional brachytherapy boost was added to the external
beam radiation. Analyses, in the present study, by both
intention-to-treat and by actual treatment received, showed
no differences between both arms with respect to 3 year
overall survival (p = 0.819 and p = 0.742, respectively)
and local relapse free survival (p = 0.906 and p = 0.496,
respectively).
Patient characteristics were equally distributed be-
tween the two randomized groups with the exception of
age where the brachytherapy patients were younger by
approximately 3.5 years (p = 0.044). Thus patients in the
study arm may have a relative advantage since older age
is a worse prognostic factor. In spite of this, the addition
of brachytherapy did not significantly improve patient’s
outcome in this study.
Ozyar et al. [17] multivariate analysis showed that ad-
vanced nodal status was a strong significant unfavour-
able factor for DFS. Sham et al. [20] confirmed that
nodal stage was prognostically significant even among
patient groups stratified by size and degree of fixation of
the neck nodes involved. Furthermore, in the present
<40 yrs105 80 57 35 11 0 ---
40 yrs or more168 113 76 46 15 3 0
Figure 7 Local recurrence free survival by age. Improved RFS for
patients younger than 40 years (p = 0.058).
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http://www.ro-journal.com/content/9/1/67study, patients with more advanced disease (T3-4, N2-3)
were also found to have a worse 3-year overall survival
(p = 0.024) (Figure 5), disease free survival (p = 0.018)
and local relapse free survival (p = 0.016) (Figure 6).
Sham and Choy [20] evaluated the records of 759 Stage I
to IV nasopharyngeal carcinoma patients and found that
the 5 years survival of patients less than 40 years old was
better than those who were older. In the present study,
age (<40 years versus > 40 years) significantly affected
LRFS (p = 0.058) (Figure 7) and OS (p = 0.014) (Figure 8)
at 3 years.
A meta-analysis of 8 trials by Baujat et al. [21] confirmed
a survival benefit for cisplatin-based chemotherapy, a result
similar to the Intergroup Study 0099 protocol [5] which
showed chemoradiation to be superior for advanced naso-
pharyngeal carcinoma with respect to progression free sur-
vival and overall survival. The study by the Intergroup 0099
was the first to document a significant survival benefit for
chemoradiaton versus radiotherapy alone. This has been
confirmed by subsequent trials. As of today, it is not clear
whether the adjuvant chemotherapy component of the
Intergroup regimen contributed to its survival benefit. It is
to be noted that the present study differed from the Inter-
group study in that patients received neoadjuvant chemo-
therapy and concomitant chemoradiation but not adjuvant
chemotherapy.
Cisplatin-based neoadjuvant or induction chemother-
apy induces dramatic initial responses and good toler-
ability. Initial response rate is in the order of 93% with a
20% complete remission rate followed by 86% complete
remission rate after radiotherapy [22]. One recent ran-
domized phase II trial [23] demonstrated an overall sur-
vival benefit with cisplatin-docetaxel when compared to
chemoradiotherapy alone. Two prospective clinical trials
are currently underway. Other studies however, failedT1&2; N1 203 150 110 69 24 3 0
T3&4; N2&3 70 43 23 12 2 0 ---
Figure 6 Local recurrence free survival by stage. Statistically
significant benefit in local recurrence free survival for patient with
early disease (p = 0.016).to demonstrate any benefit [24,25] for the neoadjuvant
strategy.
In this study, 155 patients (57%) initiated treatment
with the cisplatin-doxorubicin combination and 118 pa-
tients (43%) with cisplatin-5FU combination, due to the
local treatment policy in one centre. Patient characteris-
tics were equally distributed between the groups who
received cisplatin/doxorubicin versus those receiving
cisplatin/5FU. With regard to treatment arm, there were
5% more patients from the brachytherapy arm who com-
pleted the planned chemotherapy, which could poten-
tially enhance results for the brachytherapy arm.
In a retrospective analysis of 145 patients, Leung et al.
[18] reported that the 5 year major-complication-free
survival rate was 89.5% for the brachytherapy group and
85.6% for the control group (p = 0.23). Similar to our
study, there were no differences in major toxicity be-
tween patients receiving external radiation alone and<40 yrs105 91 69 46 19 1 0
40 yrs or more168 131 94 55 24 5 0
Figure 8 Overall survival by age. There is an advantage in overall
survival for patients younger than 40 years (p = 0.014).
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http://www.ro-journal.com/content/9/1/67patients receiving intracavitary brachytherapy where the
following were evaluated: skin (p = 0.277), subcutaneous
tissue (p = 1.0), mucous membranes (p = 0.209), salivary
glands (p = 0.806), brain (p = 1.0), and trismus (p =
0.687). Patients commonly experienced low grade side
effects such as mucous membrane mucositis and xeros-
tomia. Conversely, high grade toxicity was not com-
monly observed with the exception of severe trismus
in 15 patients in the control and 12 patients in the
brachytherapy arm. It is important to note that longer
follow-up may be required to observe late complications
as nasopharyngeal ulceration and cranial nerve palsy as
were reported by Teo et al. [16] where the median follow
up were 49.4 months and 38.5 months for these two
complications, respectively.
Levendag et al. [26] performed a pooled analysis includ-
ing the patients in this study (n = 274) with two additional
cohorts of patients with NPC treated in Rotterdam (n = 94)
and Amsterdam (n = 89). The pool comprised a total of 457
patients. Thirty three patients were excluded because of
having early (T1-T2 N0) disease. No significant difference
in local recurrences was observed for the T3-T4 N+ tu-
mours. However, for T1-T2 N+ tumours, significant differ-
ences in local control were found between patients treated
with or without a brachytherapy boost in the pooled ana-
lysis, thus confirming previous studies for patients with
early local disease.
This study is an example of the possibility of per-
forming clinical trials in an international setting in
developing countries on a common disease such as
nasopharyngeal carcinoma. The overall results in terms
of local tumour control, loco-regional control and sur-
vival appear lower than those in series from China
using advanced conformal radiotherapy techniques.
Notwithstanding the fact that this was a selected poor
risk population of patients with advanced loco-regional
disease, the reasons for this difference remain to be
explored.
In conclusion, a clinical advantage of adding a brachy-
therapy boost in the setting of loco-regionally advanced
nasopharyngeal carcinoma treated with cisplatin-based
induction chemotherapy and combined chemo radio-
therapy has not been demonstrated in this study.
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